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Abstract
Background: Linoleic acid, with a DRI of 12-17 g/d, is the most highly consumed polyunsaturated fatty acid in the
Western diet and is found in virtually all commonly consumed foods. The concern with dietary linoleic acid, being
the metabolic precursor of arachidonic acid, is its consumption may enrich tissues with arachidonic acid and
contribute to chronic and overproduction of bioactive eicosanoids. However, no systematic review of human trials
regarding linoleic acid consumption and subsequent changes in tissue levels of arachidonic acid has been
undertaken.
Objective: In this study, we reviewed the human literature that reported changes in dietary linoleic acid and its
subsequent impact on changing tissue arachidonic acid in erythrocytes and plasma/serum phospholipids.
Design: We identified, reviewed, and evaluated all peer-reviewed published literature presenting data outlining
changes in dietary linoleic acid in adult human clinical trials that reported changes in phospholipid fatty acid
composition (specifically arachidonic acid) in plasma/serum and erythrocytes within the parameters of our
inclusion/exclusion criteria.
Results: Decreasing dietary linoleic acid by up to 90% was not significantly correlated with changes in arachidonic
acid levels in the phospholipid pool of plasma/serum (p = 0.39). Similarly, when dietary linoleic acid levels were
increased up to six fold, no significant correlations with arachidonic acid levels were observed (p = 0.72). However,
there was a positive relationship between dietary gamma-linolenic acid and dietary arachidonic acid on changes in
arachidonic levels in plasma/serum phospholipids.
Conclusions: Our results do not support the concept that modifying current intakes of dietary linoleic acid has an
effect on changing levels of arachidonic acid in plasma/serum or erythrocytes in adults consuming Western-type
diets.
Background
Arachidonic acid (AA, 20:4 n-6) is a potent bioactive
molecule. When released from membrane phospholi-
pids, it is converted to a variety of bioactive compounds,
called eicosanoids. These oxidized lipid molecules are
related to a number of chronic diseases including cardi-
ovascular disease, cancer and inflammation [1-4].
Enrichment of AA in tissues is positively correlated with
the production of eicosanoids. Linoleic acid (LA, 18:2
n-6) is the major dietary polyunsaturated fatty acid
(PUFA) in the Western diet and is a metabolic precur-
sor to AA, linked biochemically via two desaturases and
an elongase. Typical intakes of LA are 12-17 grams per
day for women and men, respectively [5], or approxi-
mately 6% of energy. In the absence of other omega-6
(n-6) PUFA (including dietary AA), dietary LA is the
sole contributor to tissue AA. This relationship had
been established in experimental rodent models where
dietary LA was correlated with tissue AA content in a
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ground diets [6] and lipid-rich diets [7].
Recent reviews suggest this relationship may exist in
adult humans consuming a typical Western-type diet
[8,9] and some have recommended limiting LA intake
as a way to help reduce tissue AA levels [10,11]. Cer-
tainly, this relationship had been reported in subjects
consuming diets containing LA at levels less than 2% of
energy [12]. There are, however, a number of recent
papers suggesting that increasing dietary LA does not
increase tissue AA levels, but in fact may have an
inverse relationship [13,14]. To compound the complex-
ity of this relationship, the family of n-6 PUFA are, in
general, synonymously identified to dietary LA, while
seemingly ignoring other members who can contribute
to tissue AA, i.e., dietary gamma-linolenic acid (GLA,
18:3 n-6) and AA.
This study was designed to explore the relationship of
dietary LA and tissue AA, viz., phospholipid pools of
plasma/serum and erythrocytes. To our knowledge, this
is the first study to review the literature as to whether
increasing dietary LA is positively correlated with
increasing tissue AA content, and whether reducing
dietary LA has the opposite effect in adults consuming
Western-type diets. We further investigated what poten-
tial contributions other dietary n-6 PUFA may have on
tissue AA content. This study was limited in scope and
did not address other controversial issues related to
dietary LA or other PUFA or their effects on issues
related to health.
Methods
The aim of this paper was to identify, review, and evalu-
ate all peer-reviewed published literature presenting data
outlining changes in dietary LA in adult human clinical
trials which report phospholipid fatty acid composition
(specifically AA) in plasma/serum and erythrocytes. We
chose the phospholipid pool in plasma/serum because
here is where a majority of the human data is, it repre-
sents membranes of lipoproteins derived from the sur-
face of hepatic endoplasmic reticulum [15] (it helps to
control for potential variations in other components,
such as circulating triglycerides). The studies reporting
the fatty acid composition of erythrocyte phospholipids
do so because fatty acids in erythrocytes are almost
totally esterified in phospholipids. Further refinements
to the search strategy included reported changes in
tissue AA levels following dietary intake of AA and its
various n-6 PUFA precursors, i.e., LA and GLA. Pub-
lished articles meeting eligibility criteria from 1970 to
present were reviewed, of which 4336 articles were
retrieved from May 2009 - November 2009 (Figure 1).
The primary search engine used was PubMed.gov (The
National Library of Medicine, National Institutes of
Health), along with several prominent nutrition-based
clinical journals, i.e., American Journal of Clinical Nutri-
tion, British Journal of Nutrition, and any additional
citations in articles reviewed. The search terms included
linoleic acid, g-linolenic acid, gamma-linolenic acid, ara-
chidonic acid, omega-6, n-6, olive oil, soybean oil, sun-
flower oil, safflower oil, corn oil, omega-3, n-3, plasma,
erythrocyte, red blood cell and phospholipid.
The following eligibility criteria applied to all accepted
articles. Subjects had to be 18 years or older with no
known metabolic disorder that would influence tissue
AA content. Sufficient data on LA, GLA and/or AA
consumption (pre- and post-intervention) was required.
The nature of the intervention (i.e., capsules, oils or
dietary modifications) had to be presented. The fatty
acid data (plasma/serum and/or erythrocyte) had to be
determined from fasting patients, pre- and post-supple-
mentation. Baseline and post-treatment of tissue phos-
pholipid fatty acid composition had to be provided. On
occasion, percent changes in tissue fatty acid composi-
tion were provided and this data was used. Only those
papers published after 1970 due to improved gas chro-
matographic methods were accepted. Articles were auto-
matically excluded if subjects were less than 18 years
old, pregnant or nursing, consuming supplements con-
taining long chain n-3 fatty acids or supplemented fish
intake above and beyond their typical dietary regimen,
or using known inhibitors of AA metabolism, such as
non-steroidal anti-inflammatory drugs (NSAIDs).
After an initial review of the papers, 4043 were
excluded because of insufficient data or studies that
did not investigate our parameters. Of the 293 papers
that passed the initial review process, each was
reviewed by two independent investigators (BR and
JW) and thirty-six were acceptable by both reviewers.
Those papers that were not accepted (n = 249) were
rejected because baseline data was not sufficiently
reported, data for target tissues was not presented,
insufficient data was present and did not allow for
appropriate calculations, background diets were not
sufficiently described, or they included supplementa-
tion of restricted food items (i.e., long chain n-3
PUFA). Thirty-six articles were found to meet all of
the inclusion-exclusion criteria.
Once accepted, data on dietary n-6 fatty acid intake (%
of calories or g/d) and tissue AA content were extracted.
Study design, number and gender of subjects, method of
supplementation (i.e., type of oil, capsules or food com-
ponent used) were recorded. Those studies involving
dietary LA as percentage of calories or g/d and its
effects on changes in tissue AA content are summarized
in Tables 1, 2, &3. Similarly, those studies involving
dietary GLA (0.36-6.00 g/d) and AA (0.50-6.00 g/d) are
summarized in Tables 4 and 5. If a study met the
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son, each comparison was reported as a separate data
point.
Baseline tissue AA levels were defined as relative
abundance of AA in tissue phospholipids prior to diet-
ary supplementation (or reduction) of the corresponding
dietary n-6 PUFA of interest (i.e., LA, GLA or AA). In
the case of cross-over designs, baseline fatty acid com-
position was established following a washout period or
after supplementation of a control diet if there were no
or only minor changes in the dietary n-6 PUFA content.
For example, a supplement rich in oleic acid (a mono-
unsaturated fatty acid typically used as a control and
known to have a neutral effect on tissue AA content)
could be used as a control lipid (or oil) prior to supple-
mentation of an equal amount of a lipid (or oil) rich in
LA. Percent change for each dietary n-6 fatty acid of
interest was used to standardize the relative differences
between baseline intakes and intervention intakes
following the experimental period using the following
formula:
intervention intake - baseline intake
baseline intake
× 100
The levels of intake were based on the relative caloric
amount (% of calories), and when this data was not
available absolute intake levels (g/d) were used. Percent
change for tissue AA content was used to standardize
the relative differences between baseline levels and inter-
vention levels following the experimental period using
the following formula:
post - intervention level - baseline level
baseline level
× 100
Articles accepted (36) 
Review of papers by two 
reviewers for relevance and 
inclusion (293) 
Articles that included baseline 
diet and/or supplementation 
amount and phospholipid data 
(293)
Articles retrieved from 
electronic sources (ex. 
PUBMED, AJCN, BJN etc..) 
and references  (4336) Articles not accepted due to 
insufficient or missing data;  or 
otherwise not suitable for our research 
objective (4043)
Articles not accepted by both reviewers 
because of design flaws, lack of 
sufficient data for analysis/baseline 
data not sufficiently reported, data for 
target tissues not presented, insufficient 
data describing n-6 supplementation, 
supplementation of long chain n-3 
PUFA/fish/fish oils, or based on 
inclusion/exclusion criteria (249)
Figure 1 Schematic outlining the systematic review.
Rett and Whelan Nutrition & Metabolism 2011, 8:36
http://www.nutritionandmetabolism.com/content/8/1/36
Page 3 of 15Table 1 Studies outlining the effects of decreasing dietary linoleic acid levels (% energy) from baseline on changes in plasma/serum phospholipid
arachidonic acid level
Author,
(reference)
Study design Subjects Diet
length
Diet comparison LA (% change)
Baseline to
intervention
ΔAA (%)
change
Comments
Lasserre [17] Randomized
crossover
N = 24 5 months Peanut oil diet (baseline)
compared to milk fat diet
-90 (6.5%-0.6% ) 9.99 N.S. Used peanut oil group b/c close to DRI for LA. Subjects were nuns in
monastery.
Peanut oil diet (baseline)
compared to low erucic acid
rapeseed oil (canola oil) diet
-30 (6.5%-4.5%) -5.49 N.S. Used peanut oil group b/c close to DRI for LA. Subjects were nuns in
monastery.
Lichtenstein
[35]
Randomized
double-blind
crossover
N = 30 35 days Soybean oil diet (baseline)
compared to high oleic acid
soybean oil diet
-82 (11%-1.9%) -2.58 N.S. Pooled data of men and women. Baseline diet of 10.96% energy
closest to DRI for LA. AA did not differ among remaining groups
tested either
Liou [37] Randomized
crossover
N = 24 4 weeks High linoleic acid sunflower oil
(diet) compared to high oleic
acid safflower oil (diet)
-63 (10.5%-3.8%) -5.55 N.S. Incorporated test oils into baked foods (cookies, breads), mayonnaise,
salad dressing. AA data presented in graphs, not tables. Fish intake
was avoided for all groups. AA PL content did not differ between
sequence of diets going from high LA to low LA or vice versa. Study
address low or high LA with constant ALA at 1%.
Goyens [38] Double-blind
intervention
N = 19 6 weeks Reduced LA in food items
(margarines, pastries, baked
goods)
-57 (7%-3%) 5.26 N.S. Test oils consumed in margarine and pastries. Prohibited consumption
of fish or marine foods in all groups.
Vega-Lopez
[36]
Randomized
crossover
N = 15 35 days Canola oil diet compared to
palm oil diet
-50 (6.5%-3.3%) -8.06 N.S. Canola oil in mixed foods was replaced by palm oil in mixed foods.
AA did not change among all three dietary groups. Canola oil diet is
baseline because closest to DRI LA intake.
Li [39] Parallel
intervention
N = 17 28 days High LA diet to moderate LA
diet using canola oil/canola
margarine
-48 (13.5%-7%) -3.80 N.S Subjects were given diet more than twice DRI for LA and then given
diet resembling the DRI for LA. All groups were asked to not consume
fish.
High LA diet to normal LA diet
using canola oil/canola
margarine
-39 (11.9%-7.3%) -16.5 N.S.
Mantzioris
[40]
Parallel
intervention
N = 15 4 weeks Control diet (sunflower oil)
group compared to
intervention diet (flaxseed oil)
-57 (7.8%-3.3%) -4.5 N.S. Control group consumed relatively close to DRI for LA while
intervention group reduced LA by more than half.
King [16] Randomized
parallel
N = 66 6 weeks Baseline diet compared to low
fat diet
-29 (10%-7.1%) 4.1 (p < 0.05) Used modified food items for diets containing different amounts of
fat. Reported AA PL in % change.
Geppert [41] Randomized
double- blind
intervention
N = 54 8 weeks Baseline diet compared to LA
reduced diet (using olive oil
capsules)
-12 (5.8%-5.1%) 1.12 N.S. Used olive oil capsules with vegetarians.
Percent change (±) from baseline in AA that is significant is identified with (p < 0.05). Percent change (±) from baseline in AA that is not significant is denotedby N.S.
Abbreviations: AA, arachidonic acid; DRI, Dietary Reference Intake; LA, linoleic acid; PL, phospholipid
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5Table 2 Studies outlining the effects of increasing dietary linoleic acid levels (% energy) from baseline on changes in plasma/serum phospholipid arachidonic
acid level
Author,
(reference)
Study
design
Subjects Diet length Diet comparison LA (%
change)
Baseline to
intervention
Δ AA (%)
change
Comments
King [16] Randomized
parallel
intervention
N = 33 6 weeks Baseline diet compared to moderate fat
diet
13 (10.3%-
1.6%)
-3.2 (p < 0.05) Used modified food items for diets containing different
amounts of fat. Reported AA PL as % change.
Thijssen [42] Randomized
multiple
crossover
N = 45 5 weeks Stearic acid diet to oleic acid diet in
food items (using margarines, breads,
sponge cakes)
14 (2.1%
-2.4%)
-2.24 (N.S.) No order to diets given. Subjects received all 3 diets with
varying amounts of LA.
Oleic Acid to LA food items (margarines,
breads, sponge cakes)
287 (2.4%-
9.3%)
-1.15 (N.S.) No order to diets given. Subjects received all 3 diets with
varying amounts of LA.
Montoya
[43]
Sequential
interventions
N = 41 4 weeks From palm oil based diet compared to
olive oil based diet
16 (3.2%-3.7%) 4.82 (N.S.) Used nuns and priests. Everyone consumed same sequence of
diets. AA did not change among the three test diets. No
crossover, subjects were their own controls.
Olive oil based diet to sunflower oil base
diet
230 (3.7%-
12.2%)
-3.44 (N.S.)
Lichtenstein
[35]
Randomized
double-blind
crossover
N = 30 35 days Baseline soybean oil diet compared to
low saturated fat-soybean oil diet. The
soybean oils varied in LA composition
15.8 (11%
-12.7%)
0.89 (N.S.) Pooled data of men and women. Five diets of random order.
Subjects visited metabolic kitchen 3 times week. Varying LA
amounts using modified soybean oils.
Baseline high oleic-soybean oil diet to
low ALA-soybean oil diet
552 (1.9%-
2.5%)
1.27 (N.S.)
Li [39] Parallel
intervention
N=1 0
N=7
14 days 14
days
Baseline Western diet to intervention diet
increased in LA intake using safflower oil
17.8 (10.1%-
11.9%)
6.18 (N.S.) Used safflower oil/safflower margarine to increase LA in diet to
almost twice DRI of LA. AA did not differ among all groups in
study.
Baseline Western diet to intervention diet
increased in LA intake using safflower oil
82.4 (7.4%-
13.5%)
0.96 (N.S.) Used safflower oil/safflower margarine to increase LA in diet to
more than twice DRI of LA. AA did not differ among all groups
in study.
Vega-Lopez
[36]
Randomized
crossover
N = 15 35 days Canola oil diet compared to soybean oil
diet
64.2 (6.5%-
10.7%)
-2.35 (N.S.) Canola oil in mixed foods was replaced by soybean oil in mixed
foods. AA did not change among all three dietary groups.
Canola oil diet is baseline because close to the DRI for LA.
Liou [37] Randomized
crossover
N = 22 4 weeks Low LA diet (high in oleic acid safflower
oil) compared to high LA diet (high in
sunflower oil)
176 (3.8%-
10.5%)
-0.18 (N.S.) AA PL content presented as graphs, not numerically. Fish was
avoided in all dietary groups. ALA intake was kept constant
between low/high diet.
Valsta [19] Randomized
crossover
N = 39 6 weeks Habitual diet compared to high LA
trisunflower oil diet
86 (4.2%-7.8%) 10 (p < 0.05) Fish cut in half in all dietary groups. Has a baseline for before
each diet. Used trisunflower oil in margarine, food oil, salad
dressing, bread, cake and cookies, in place of habitual foods.
Habitual diet compared to high ALA
rapeseed oil diet
45 (4.2%-6.1%) 2.77 (N.S.)
Raatz [18] Randomized
crossover
N = 10 28 days Low fat diet (20% energy) compared to
high fat diet (45% energy).
100 (6%-12%) -16 (p < 0.05) Modified foods rich in LA. Random order to diet, so baseline
was chosen based on DRI of LA. Used washout period of 21-28
days
Lasserre [17] Randomized
crossover
N = 24 5 months Peanut oil diet compared to sunflower
oil
111 (6.5%-
13.7%)
-20 (p < 0.05) Used peanut oil group b/c close to DRI for LA.
Innis [13] Randomized
crossover
N = 24 8 weeks Low LA diet to high LA diet 176 (3.8%-
10.5%)
1.86 (N.S.) Controlled for dietary AA.
Percent change (±) from baseline in AA that is significant is identified with (p < 0.05). Percent change (±) from baseline in AA that is not significant is denoted by N.S.
Abbreviations: ALA, alpha-linolenic acid; AA, arachidonic acid; DRI, Dietary Reference Intake; LA, linoleic acid; PL, phospholipid
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5Table 3 Studies outlining the effects of supplementing dietary linoleic acid levels (g/day) on changes in plasma/serum
phospholipid arachidonic acid level
Author,
(reference)
Study design Subjects Diet
length
LA source, amount
supplemented (g/d)
Δ AA (%)
change
Comments
Anderson
[44]
Parallel intervention N = 8 3
months
Olive oil (0.2) 8.46 (N.S.) Olive oil supplement
N = 9 Olive oil (0.2) 9.05 (N.S.) Provided LA for two different
groups
Thies [45] Randomized, double-blind,
parallel intervention
N=8 1 2
weeks
Oil blend (0.64) 3.38 (N.S.) Different oil blends were
sources of LA
Placebo oil (0.9) 5.25 (N.S.)
Geppert [21] Randomized double- blind
parallel intervention
N = 20 8 weeks Oil blend (0.86) -7 (p < 0.05) Blend palm, rapeseed and
sunflower oil
Johansson
[46]
Randomized, double-blind,
crossover
N = 12 4 weeks Sea buckthorn berry oil
(0.90)
-2.2 (N.S.) Sea buckthorn berry oil is
17.9% LA.
Kew [47] Double-blind, parallel
intervention
N = 42 4 weeks Olive oil (0.92) -13.04 (N.S.)
Buckley [48] Double-blind parallel
intervention
N = 45 4 weeks Olive oil (0.95) -7.14 (N.S.)
Yaqoob [34] Randomized, double- blind
parallel intervention
N = 8 per
group
12
weeks
Placebo (coconut/soybean
oil) (1.0)
20 (N.S.)
Olive oil (1.2) -2.1 (N.S.)
Sunflower oil (6.95) 16 (N.S.)
Wallace [49] Randomized, double- blind
parallel intervention
N=8 1 2
weeks
Oil blend (1.52) -6.97 (N.S.)
N = 8 palm/soybean oil (1.7) 2.43 (N.S.)
Miles [27] Randomized, double-blind
parallel intervention
N=8 1 2
weeks
Placebo (palm/sunflower oil)
(2.07)
2.19 (N.S.)
Grimsgaard
[20]
Double-blind, parallel
intervention
N = 78 7weeks Corn oil (2.24) 3.1 (p <
0.05)
Conquer [50] Double-blind, parallel
intervention
N = 24 42 days Corn oil (2.39) 1.12 (N.S.)
Finnegan [51] Double-blind, parallel
intervention
N = 50 6
months
Safflower/sunflower (11.6) 7.19 (N.S.) Test oils provided as
margarine and capsules
Percent change (±) from baseline in AA that is significant is identified with (p < 0.05). Percent change (±) from baseline in AA that is not significant is denoted by N.S.
Abbreviations: AA, arachidonic acid; DRI, Dietary Reference Intake; LA, linoleic acid
Table 4 Studies outlining the effects of supplementing dietary gamma-linolenic acid on changes in plasma/serum
phospholipid arachidonic acid level
Author,
(reference)
Study design Subjects Diet
length
GLA source, amount
supplemented (g/d)
Δ AA (%)
change
Comments
Ebden [52] Double-blind
intervention
N=6 8
weeks
Efamol oil (0.36) 6.1 (N.S.) No crossover with placebo. Subjects were asthmatics
used medication or bronchodilator.
Thavonen
[29]
Randomized, double-
blind crossover
N = 15 3
weeks
Black current seed oil
(0.38)
3.7 (N.S.) Subjects aged 55-75 years old
Theis [45] Double-blind parallel
interventions
N=8 1 2
weeks
GLA-rich triacylglycerol
capsules (0.77)
27 (p <
0.05)
Subjects consumed capsules for 12 weeks. AA
changed only on 12
th week.
Yaqoob
[34]
Double-blind parallel
intervention
N=8 1 2
weeks
Evening primrose oil
(1.06)
14 (N.S.)
Mills [28] Randomized double-
blind parallel
intervention
N = 10 28
days
Borage oil (1.30) 12 (p <
0.05)
AA data available for only pre and post intervention
(28 days)
Miles [27] Randomized double-
blind intervention
N = 8-12 12
weeks
Borage oil capsules
(2.00)
15 (p <
0.05)
Consumed capsules for 12 weeks. AA only increased
after the 8th week, no difference after 8
th week.
Johnson
[53]
Pre-post intervention N = 5 3
weeks
Ultra-GLA capsules
(6.00)
31 (p <
0.05)
Percent change (±) from baseline in AA that is significant is identified with (p < 0.05). Percent change (±) from baseline in AA that is not significant is denoted by N.S.
Abbreviations: AA, arachidonic acid; GLA, gamma-linolenic acid
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The overall linear correlation between percent change of
dietary n-6 fatty acids and percent change of tissue AA
was computed using the Proc Corr procedure in SAS
9.2 (SAS Institute Inc. SAS Campus Drive, Cary, North
Carolina). The correlation matrix and the T statistic
tested for correlation and statistical significance, respec-
tively. For the linear correlations, the equation of the
line was computed, and represented by y = mx for those
that exhibited linearity. Data not resembling a linear
relationship (i.e. dietary GLA and AA) utilized a polyno-
mial growth curve from SAS General Linear Model and
t-tests for model parameters tested for significance. P-
values less than or equal to 0.05 were considered signifi-
cant. The Y values represent changes of AA (% from
baseline) and the X values represent the changes of the
various dietary n-6 PUFA (% from baseline or g/d sup-
plemented). In addition to the overall correlation test,
the statistical significance for each individual data point
(for changes in tissue AA), as reported by the authors in
their respective manuscripts, was identified in each
graph. If the changes from baseline were significantly
different the data was represented by triangle. If the
changes from baseline were not statistically different,
they were represented by a diamond.
Results
Eleven comparisons reported decreases in LA intakes
(-12% to -90%) and no significant correlations were
associated with changes in plasma/serum phospholipid
AA content (r
2 = 0.07, p = 0.44, y = 0.026x) (Table 1
and Figure 2). Only one study of the eleven reported a
significant change, a 4.1% increase in AA content, fol-
lowing a 29% reduction in LA intake [16].
Increases in dietary LA, ranging from 12%-550%, was
not significantly correlated with changes in plasma/
serum phospholipid AA content (r
2 =0 . 0 7 4 ,p=0 . 4 5 ,y
= -0.0053x) (Table 2 and Figure 3). Of the sixteen com-
parisons, only four studies reported significant changes
in AA levels when dietary LA levels were increased;
three studies reported 3-20% reductions following 12%-
110% increases in LA consumption [16-18] and only
one study reported a significant increase in AA content
(10%) following an 86% increase in LA intake [19]. Sub-
dividing the studies by design (crossover versus non-
crossover) had no effect on the results (data not shown).
Similarly, in those studies that only reported absolute
levels of LA supplementation (g/d), increasing LA sup-
plementation was not significantly correlated with
changes in plasma/serum phospholipid AA content (r
2
= 0.092, p = 0.64, y = 0.969x) (Table 3 and Figure 4). Of
the seventeen comparisons, only two were significantly
different, one resulted in an increase in AA content by
3% following supplementation of 2.24 g/d of LA [20]
and the other resulted in a reduction of AA content by
7% following supplementation of 0.86 g/d [21].
Similar comparisons were made in erythrocytes with
increasing and decreasing intakes of LA, although the
number of studies were more limited. Increases in diet-
ary LA, ranging from 12%-100%, were not significantly
correlated with changes in tissue AA content (r
2 =0 . 0 6 ,
p = 0.75, y = -0.1479x) (Figure 5). Reducing dietary LA
intake (-12% to -70%) was not significantly correlated
with changes in tissue AA content (r
2 = 0.017, p = 0.77,
y = -0.0174x) (Figure 6). In addition, out of the seven
studies, only one study reported a significant change
where decreasing dietary LA intake by 29% resulted in a
4% increase in AA content [16].
Table 5 Studies outlining the effects of supplementing dietary arachidonic acid on changes in plasma/serum
phospholipid arachidonic acid level
Author,
(reference)
Study design Subjects Diet length AA source, amount
supplemented (g/d)
Δ AA (%)
change
Comments
Sinclair [54] Parallel intervention N = 4 7 days White meat/eggs (0.50) 52 (p <
0.05)
Consumed AA rich, low fat diet
Ishikura [55] Double-blind crossover N = 25 1 month SUNTGA40S capsules
(0.72)
27 (p <
0.05)
Derived from Mortierella alpina
Theis [45] Randomized, double-blind,
parallel intervention
N = 48 12 weeks ARASCO (0.68) 85 (p <
0.05)
Derived from Mortierella alpina
Kusmoto
[56]
Double-blind intervention N = 12 4 weeks SUNTGA40S (0.84) 45 (p <
0.05)
Derived from Mortierella alpina
Nelson [57] Single blind crossover
intervention
N = 10 50 days ARASCO (1.49) 85 (p <
0.05)
Had 65 day washout period.
Derived from Mortierella alpina
Seyberth
[58]
Single blind intervention N = 4 2-3 weeks,
depending upon
subject
Capsules, AA ethyl ester
(6.00)
136 (p <
0.05)
Averaged from all 4 subjects
Percent change (±) from baseline in AA that is significant is identified with (p < 0.05). Percent change (±) from baseline in AA that is not significant is denoted
by N.S.
Abbreviations: AA, arachidonic acid
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Figure 2 Effects of decreasing dietary linoleic acid (LA) intake (% change) based on energy on changes in plasma/serum phospholipid
arachidonic acid (AA) content. Significant changes (p < 0.05) in AA as reported in the original papers are designated as triangles. Non-significant
AA changes as reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; LA, linoleic acid; PL, phospholipid.
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Page 9 of 15Seven studies met our criteria for the effects of GLA
supplementation on changes in plasma/serum phospholi-
pid AA content (Table 4 and Figure 7). There appeared
to be a dose dependent increase in AA content with
increasing intakes of GLA (ranging from 0.36 g/d to 6.00
g/day). This positive correlation (r
2 = 0.75, p = 0.03, y =
0.004x + 7.36) was significant with a linear regression
model, and approached significance with a non-linear
(quadratic) regression model (r
2 = 0.56, y = -1.4x
2 +
13.76x, p = 0.079). The number of available data may be
a factor in these results. Of the six GLA data points, four
of them reported statistically significant increases in AA.
Similiarly, increasing dietary AA (0.50 g/d to 6.00
g/day) was positively correlated with increases in
plasma/serum phospholipid AA content using a quadra-
tic regression model (r
2 = 0.79, y = -8.7x
2 + 74.87x,
p=0 . 0 1 3 )( F i g u r e8 ) .A l ld a t ap o i n t sw e r er e p o r t e da s
significantly different (Table 5).
Discussion
Arachidonic acid is arguably the most important PUFA
associated with membrane phospholipids. Upon release,
AA can be enzymatically metabolized to a myriad of
bioactive derivatives, eicosanoids, known to contribute
to a variety of chronic diseases, but are also known to
be involved in tissue homeostasis and the resolution of
inflammation [1-4,22]. The relative abundance of AA in
membrane phospholipids positively influences eicosa-
noid production [23]. It is well known that dietary
PUFA can affect tissue AA levels; however, what is
uncertain and controversial is whether modifying cur-
rent intakes of dietary LA will result in concomitant
changes in tissue AA content, i.e., increasing LA intake
results in an increase in tissue AA content and decreas-
ing LA has the opposite effect [8]. The goal of this
paper was to ascertain the relationship between dietary
LA and tissue AA content (phospholipid pools of
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Figure 6 Effects of decreasing dietary linoleic acid (LA) (% change) based on energy on changes in erythrocyte (RBC) phospholipid
arachidonic acid (AA) content. Significant changes (p < 0.05) in AA as reported in the original papers are designated as triangles. Non-
significant AA changes as reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; LA, linoleic acid; PL,
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Page 10 of 15plasma/serum and erythrocytes) in adults consuming a
Western-style background diet. It was not designed to
address other controversies surrounding the issues of
dietary n-6 or n-3 PUFA or in other population groups.
Many papers interchange the more general term n-6
PUFA for dietary LA, but there are two major n-6
P U F A ,L Aa n dA A ,t h a ta r ed i s t r i b u t e du n e v e n l yi nt h e
Western diet. While LA is the major PUFA in most
commonly consumed foods, AA is exclusively found in
animal products, such as, muscle, organ meats and eggs
[24]. They have distinct biological activities that are bio-
chemically linked via desatuation and elongation, and as
such, LA is the conditionally essential fatty acid. Linoleic
acid is specifically required in the skin to maintain the
integrity of the epidermal water barrier and AA is the
immediate precursor to eicosanoids, as well as being the
n-6 PUFA selectively incorporated into the membranes
of certain tissues, i.e., brain [25]. When consumed (LA
vs. AA), they appear to have differential effects on tissue
fatty acid composition, where AA appears to more
robustly modify tissue AA levels and eicosanoids [14,26].
The data presented in this paper suggests that a dose
response between dietary LA and tissue AA does not
exists within the backdrop of individuals consuming a
Western-type diet. Increasing LA by as much as 551%
from baseline and reducing LA by as much as 90% from
baseline failed to yield compelling evidence supporting
the concept that any conversion of dietary LA to down-
stream metabolites results in tissue enrichment of AA, a
notion commonly assumed. For example, “However,
the higher concentrations of LA typically found in the
Western diet results in a greater conversion of LA to ara-
chidonic acid” [8] and“Excessive n-6 precursors promotes
formation of AA” [9], suggesting enrichment of AA in
tissues with increases in LA intake. We chose to evalu-
ate the data by looking at changes from baseline in
tissue AA content to standardize the data from one
study to the next. Each study began with a baseline
value and we reported percent changes from that base-
line. Supplemental intakes of LA were reported based
on energy and when that value could not be determined,
we reported absolute supplemented values, and these
data were reported seperately.
As observed from the distribution of the responses,
there was wide variability. Some papers showed small
increases in tissue AA levels when dietary LA changed,
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Figure 7 Effects of increasing dietary gamma-linolenic acid (GLA) (g/d) on changes in plasma/serum phospholipid arachidonic acid
(AA) content. Significant changes (p < 0.05) in AA as reported in the original papers are designated as triangles. Non-significant AA changes as
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Page 11 of 15while other papers showed small decreases, but most of
these changes lacked significance. When there was sig-
nificance, the changes were minimal and the distribution
pattern of the data did not favor an increase or a
decrease. We chose plasma/serum and erythrocytes as
the tissues of choice because here is where the bulk of
data exists in the human literature. Erythrocytes repre-
sent a more stable pool of dietary lipids, contain very lit-
tle neutral lipids and thus represents a membrane
fraction of AA. Fasting plasma/serum phospholipid
levels primarily (but not exclusively) represents in part
phospholipids of lipoproteins that are derived from
hepatic endoplasmic reticulum [15], and this pool is
more responsive to more recent dietary PUFA intakes.
In an effort to identify why dietary LA may not modify
tissue AA levels, we reviewed the literature for dietary
GLA using the same search strategy. Was the conver-
sion of LA to AA rate-limiting, or were tissue levels of
AA saturated? Delta-6 desaturase is the rate-limiting
enzyme in the metabolism of LA to AA. GLA is a diet-
ary n-6 PUFA that enters the metabolic pathway after
the delta-6 desaturase step. If delta-6 desaturase is rate-
limiting and tissue AA content is not saturated, then
there should be evidence that including GLA in the diet
increases tissue AA levels. When GLA was supplemen-
ted as the triacylglycerol form or as a component of a
dietary oil containing GLA (i.e., blackcurrant, evening
primrose or borage oil), tissue AA content increased in
a dose responsive manner. These effects appeared to be
less prominent in those studies [27-29] that used oils
containing appreciable amounts of the more highly
unsaturated n-3 PUFA stearidonic acid, i.e., blackcurrant
[30]. When AA was supplemented in the diet, there was
further enrichment in tissue AA content above that
observed with either LA or GLA. These results suggest
that delta-5 desaturase potentially becomes rate limiting
when GLA is supplemented. The reaction mediated by
delta-5 desaturase is an intermediate step between GLA
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Page 12 of 15and AA and by-passing that step with dietary AA leads
to further enrichment. These data seem to suggest that
while dietary LA maybe a metabolic precursor for AA,
its influence on tissue levels in populations consuming
Western diets are limited by the enzymatic conversion
through delta-6 desaturase and not due to tissue satura-
t i o no fA A .T h e s ed a t aa r es u p p o r t e db yt h ep o o rr a t e s
of conversion of plasma/serum LA to AA in adults. In
tracer studies involving stable isotopes, the estimated
fractional conversion of LA to AA was between 0.3%
and 0.6% [31].
The levels of LA in the diet required to achieve essen-
tiality could be as low as 0.5-2.0% of energy in infants
[32,33] and it has been reported that tissue levels of AA
no longer respond to dietary LA intakes above 2%
energy in adults [12]. Our study was designed to chose
studies that incorporated a Western-type diet where LA
is not typically limiting, reflective of the general public.
This means a full compliment of PUFAs were being
consumed along with LA supplementation. The DRIs
for LA and alpha-linolenic acid (ALA, 18:3 n-3) are 12
g-17 g/d and 1.1 g-1.6 g, respectively (women the lower
figure, men the higher figure). This would be equivalent
to intakes approximating 6% and 0.7% of calories per
day for LA and ALA, respectively. It is not unreasonable
to think that with a background diet containing LA,
A L A ,A A ,a n dl o n g - c h a i nn - 3P U F A s ,i . e .e i c o s a p e n t a e -
noic acid (EPA, 20:5 n-3) and docosahexaenoic acid
(DHA, 22:6 n-3) at typical intakes, that modifying diet-
ary LA levels may not influence tissue AA levels. It is
possible that as LA increases in the diet it maybe com-
peting with AA for reacylation into phospholipids
[13,14,16-18,21,34].
A small number of studies modified LA intakes by
using oils that also contained some ALA, such as soy-
bean and canola oil [17,35,36], but the results from
these studies were not significant and were similar to
the other results. There could be some concern that
some of the supplemented oils contain ALA, such as
soybean oil. It must be remembered that soybean oil has
a LA:ALA ratio similar (8:1) to that found in the US
diet (10:1) and if you included or excluded these papers
the results were unaffected. We also included two
studies that supplemented LA with recommended fish
restrictions (because they met our inclusion/exclusion
criteria) [19,37]. One study (+176% LA) reported no
changes in AA levels, while the other (+86% LA)
reported a 10% increase in AA.
Some of the weaknesses of this review are reflected in
the studies that qualified for our evaluation. Most were
not designed to specifically address our research ques-
tion; however, those that were specifically designed to
evaluate the effect of dietary LA on tissue AA content
yielded results that were similar to the overall results
[13]. Each study used a different population with poten-
tially different background diets, but overall this would
better reflect the consumption patterns of the general
public. Not all studies were blinded (61% were blinded)
and dietary LA was not exclusively modified. The meth-
ods for modifying LA intakes were varied and other
dietary PUFA were not controlled for with the excep-
tions identified previously, and data for only two tissues
were evaluated. When LA was modified, it was done so
by typically changing the levels of an oil rich in LA (i.e.,
corn oil, safflower oil, sunflower oil) or foods containing
LA (as opposed to adding pure LA), reflecting how LA
would be consumed by the general public. There were no
standard length to the studies. For example, studies
involving plasma/serum ranged between 14 days-5
months, and those looking at erythrocyte data ranged
between 14-180 days. Importantly, the subjects were used
as their own controls, the studies addressed changes in
LA in relationship to Western-type diets, and the results
were not different between those studies that were dou-
ble-blind randomized placebo controlled trials (1/3) and
those that were not. Despite these weaknesses, positive
results were still identified with intakes of GLA and AA,
helping to support those results reported with LA.
Conclusions
Elevated tissue AA levels are believed to be positively
associated with eicosanoid formation and risk for a vari-
ety of chronic diseases, including cardiovascular disease,
cancer and inflammation. The literature expresses con-
cern over the fact that increasing dietary LA can poten-
tially enrich tissues with AA due to their metabolic link.
The results of this study do not support this concern.
Whereas AA levels in blood phospholipids is increased
by GLA or AA supplements, intervention studies bring
no evidence to suggest that changes in dietary LA will
modify tissue AA content in an adult population con-
suming a Western-type diet.
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